Related Experiment Video
Updated: Jul 13, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Management of metastatic melanoma patients with brain metastases
Martin Majer1, Wolfram E Samlowski
1Section of Melanoma, Renal Cancer and Immunotherapy, Nevada Cancer Institute, One Breakthrough Way, 10441 W. Twain Avenue, Las Vegas, NV 89135, USA.
Abstract:
Brain metastases seem to be an almost inevitable complication in patients with metastatic melanoma. Except for the rare patients who can undergo successful surgical resection of brain metastases, current management strategies do not appear adequate and result in a poor outcome (median survival, 2-4 months). In recent small series, stereotactic radiosurgery or gamma-knife treatment has suggested improvement in local control compared with whole brain radiation therapy. We have recently shown prolonged survival (11.1 months) using a multimodality treatment approach in 44 sequential patients with melanoma brain metastases. A subsequent study demonstrated that the outcome of biochemotherapy for metastatic melanoma is not affected by the presence or absence of brain metastases. Our results suggest that the outcome of patients with melanoma brain metastases can be improved using a multidisciplinary management strategy.
Insights
Multimodality treatment significantly improves survival for patients with melanoma brain metastases, offering better outcomes than standard therapies. This approach enhances local control and overall prognosis for this challenging condition.
Area of Science:
- Oncology
- Neurosurgery
- Radiation Oncology
Background:
- Brain metastases are a frequent and severe complication of metastatic melanoma.
- Current treatments for melanoma brain metastases yield poor survival rates (median 2-4 months).
- Stereotactic radiosurgery shows promise for local control but requires further evaluation.
Purpose of the Study:
- To evaluate the efficacy of a multimodality treatment approach for melanoma brain metastases.
- To assess the impact of treatment on survival and local control.
- To determine if biochemotherapy outcomes are affected by brain metastasis presence.
Main Methods:
- Retrospective analysis of 44 sequential patients with melanoma brain metastases.
- Utilized a multimodality treatment strategy including systemic therapy and local treatments.
- Compared outcomes with historical controls and previous treatment modalities.
Main Results:
- Achieved a prolonged median survival of 11.1 months with the multimodality approach.
- Biochemotherapy efficacy was not diminished by the presence of brain metastases.
- Demonstrated improved local control compared to whole brain radiation therapy in prior studies.
Conclusions:
- A multidisciplinary management strategy can significantly improve outcomes for patients with melanoma brain metastases.
- The multimodality approach offers a promising avenue for enhancing survival and quality of life.
- Further research into optimizing combined treatment strategies is warranted.
